Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
67.75
-1.47 (-2.12%)
Jun 13, 2025, 4:00 PM - Market closed
Incyte Revenue
Incyte had revenue of $1.05B in the quarter ending March 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to $4.41B, up 17.13% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.41B
Revenue Growth
+17.13%
P/S Ratio
3.06
Revenue / Employee
$1,686,368
Employees
2,617
Market Cap
13.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INCY News
- 2 days ago - Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
- 8 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 - Business Wire
- 12 days ago - 20 stocks primed for rapid growth while trading at half of Nvidia's valuation - Market Watch
- 18 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 4 weeks ago - Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - Business Wire
- 4 weeks ago - 20 stocks of companies showing excellent earnings-season trends even as the economy cools - Market Watch
- 6 weeks ago - Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript - Seeking Alpha